Literature DB >> 29234164

Dyslipidaemia in nephrotic syndrome: mechanisms and treatment.

Shipra Agrawal, Joshua J Zaritsky, Alessia Fornoni, William E Smoyer.   

Abstract

This corrects the article DOI: 10.1038/nrneph.2017.155.

Entities:  

Year:  2017        PMID： 29234164     DOI： 10.1038/nrneph.2017.175

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


  5 in total

1.  Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.

Authors:  Xiaoyue Pan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 2.  Kidney as modulator and target of "good/bad" HDL.

Authors:  Jianyong Zhong; Haichun Yang; Valentina Kon
Journal:  Pediatr Nephrol       Date:  2018-10-05       Impact factor: 3.714

3.  Predicting and Defining Steroid Resistance in Pediatric Nephrotic Syndrome Using Plasma Proteomics.

Authors:  Shipra Agrawal; Michael L Merchant; Jiro Kino; Ming Li; Daniel W Wilkey; Adam E Gaweda; Michael E Brier; Melinda A Chanley; Jessica R Gooding; Susan J Sumner; Jon B Klein; William E Smoyer
Journal:  Kidney Int Rep       Date:  2019-09-19

4.  The potential mechanism of Astragali Radix in the treatment of children with nephrotic syndrome.

Authors:  Xiaomin Wen; Wenxiang Wang; Mei Zheng; Bei Song
Journal:  Transl Pediatr       Date:  2021-09

Review 5.  Dyslipidemia in Kidney Disorders: Perspectives on Mitochondria Homeostasis and Therapeutic Opportunities.

Authors:  Pei-Hui Lin; Pu Duann
Journal:  Front Physiol       Date:  2020-09-03       Impact factor: 4.566
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.